Real‐World Outcomes of Acute Myeloid Leukemia Patients Undergoing Treatment With Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2
Manuel R Espinoza‐Gutarra, Brooke Jarret, Xiaoliang Wang, Anosheh Afghahi, Sejong Bae · 2026
Read Real‐World Outcomes of Acute Myeloid Leukemia Patients Undergoing Treatment With Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2 by Manuel R Espinoza‐Gutarra, Brooke Jarret, Xiaoliang Wang, Anosheh Afghahi, Sejong Bae (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13478251.txt.
Description
Espinoza-Gutarra and colleagues mined in 2026 a United States health record bank for real world results of targeted pills in acute myeloid leukemia, a fast blood cancer. The pills block one of three flawed gene switches, FLT3, IDH1, or IDH2. Trial results had looked bright, but clinic results were scarce. Their set held 482 adults treated from 2015 to 2023, some with the pill as first care and some after prior care failed.
Time on the pill ran near three and a half months in both groups. Mid survival sat near one year in both, with no clear edge for early use. Adding a second drug class did not lift scores. Younger age, prior stem cell graft, private cover, and a kind risk class each tracked with longer life. The authors call the real world yield poor across the board, and urge fresh plans for this group.
Catalog record
| CREATOR | Manuel R Espinoza‐Gutarra, Brooke Jarret, Xiaoliang Wang, Anosheh Afghahi, Sejong Bae |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |